Anixa Biosciences Inc (ANIX) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: $865.4K

ANIX ranks #5497 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

66 institutions disclose a position in ANIX, but none treat it as a major bet — even Laird Norton Wetherby Trust Company, LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

Marshall Wace, LLP has added to its ANIX position for two straight quarters, increasing it by $792.8K to reach $919.3K today.

Susquehanna International Group, LLP has trimmed its ANIX position for two straight quarters, cutting it by $737.2K while still holding $112.3K.

ANIX reported a net loss of $10.0M over the trailing twelve months.

• Not yet profitable — net loss of $10.0M over the trailing twelve months
• Revenue declined 59.2% year over year
• Net income improved year over year, from -$12.1M to -$10.0M
• Operating cash flow was negative, using $7.2M in cash
• Current ratio of 8.08x — enough short-term assets to cover short-term liabilities
• Liabilities run 6.45x equity — a highly leveraged balance sheet worth noting